The impact of clinical trials on the use of medications for acute myocardial infarction: Results of a community-based study

Archives of Internal Medicine

Volumn 156, Issue 1, 1996, Pages 54-60

  Col, Nananda F ^a,e   McLaughlin, Thomas J ^b   Soumerai, Stephen B ^b   Hosmer Jr , David W ^c   Yarzebski, Jorge ^a   Gurwitz, Jerry H ^d   Gore, Joel M ^a   Goldberg, Robert J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FIBRINOLYTIC AGENT; NIFEDIPINE; NITRATE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEMOGRAPHY; DRUG USE; ELECTROCARDIOGRAM; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ASPIRIN; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS;

EID: 0030071737     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.1.54     Document Type: Article

References (51)

1. Chalmers TC. The impact of controlled trials on the practice of medicine. Mt Sinai J Med. 1974,41:753-759
2. Friedman L, Wenger NK, Knatterud GL Impact of the coronary drug project findings on clinical practice. Control Clin Trials. 1983;4:513-522.
3. Boissel JP. Impact of randomized clinical trials on medical practices. Control Clin Trials. 1989;10(suppl 4):120S-134S.
4. Fineberg HV Clinical evaluation. how does it influence medical practice? Bull Cancer. 1987;74:333-346
5. Combs JL, Cohen SM, Fine SL, Murphy RP, Patz A. The spectrum of senile macular degeneration (SMD) at the retinal vascular center. Presented at the 42nd Scientific Meeting of the Residents Association of the Wilmer Ophthalmological Institute, 1983; Baltimore, Md.
6. Finkelstein SN, Gilbert DL Scientific Evidence and the Abandonment of Medical Technology: Study of Eight Drugs. Cambridge, Mass: Alfred P Sloan School of Management, Massachusetts Institute of Technology; 1983 1419-1483.
7. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992:327 241-247.
8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992,327 669-677
9. Rouleau JL, Moye LA, Pfeffer MA, et al A comparison of management patterns after acute myocardial infarction in Canada and the United States N Engl J Med. 1993,328:779-784
10. Ross-Degnan D, Soumerai SB, Fortess EF, Gurwitz JH. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA. 1993;270 1937-1942
11. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians Am J Med 1982,73 4-8
12. Soumerai SB, Ross-Degnan D, Gortmaker S, Avorn J Withdrawing payment for nonscientific drug therapy, intended and unintended effects of a large-scale natural experiment JAMA. 1990,263:831-839
13. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost and equity. N Engl J Med. 1987;317:550-556.
14. Soumerai SB, Ross-Degnan D. Kahn JS Effects of professional media warnings about the association between aspirin use in children and Reye's syndrome. Milbank Q 1992;70 155-182
15. Stross JK, Bole GG Evaluation of a continuing education program in rheumatoid arthritis. Arthritis Rheum. 1980,23.846-849.
16. Soumerai SB, McLaughlin TJ, Avorn J Improving drug prescribing in primary care, a critical analysis of the experimental literature. Milbank Q. 1989,67:268-317.
17. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies research in need of discipline. Milbank Q. 1993,71.217-252.
18. Goldberg RJ, Gore JM, Alpert JS, Dalen JE Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981): the Worcester Heart Attack Study. JAMA. 1986;255:2774-2779.
19. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Incidence and case fatality rates of acute myocardial infarction (1975-1984): the Worcester Heart Attack Study. Am Heart J. 1988;115:761-767.
20. Goldberg RJ, Gorak EJ, Yarzebski J, et al. A community-wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. Circulation. 1993;87:1947-1953.
21. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Therapeutic trends in the management of patients with acute myocardial infarction (1975-1984): The Worcester Heart Attack Study. Clin Cardiol. 1987;10.3-8.
22. Gore JM, Goldberg RJ, Alpert JS, Dalen JE. The increased use of diagnostic procedures in patients with acute myocardial infarction- a community-wide perspective. Arch Intern Med. 1987;147:1729-1732.
23. Goldberg RG, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991;325 1117-1122
24. Soumerai SB, Avorn J, Ross-Degnan O, Gortmaker S. Payment restrictions for prescription drugs under medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
25. Soumerai SB, Ross-Degnan D, Gortmaker S, Avorn J. Withdrawing payment for nonscientific drug therapy: intended and unintended effects of a large-scale natural experiment. JAMA. 1990;263:831-839.
26. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
27. Liang KY, Zeger SL Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
28. Zeger SL, Liang KY, Albert PS Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes Biometrics. 1986;42:121-130.
30. The American College of Cardiology and ISIS Collaborative Group. Results of a large randomised trial of intravenous streptokinase and oral aspirin in acute myocardial infarction. J Am Coll Cardiol. 1988;11:27A, 232A. Abstracts.
31. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet. 1988;2 2349-2360.
32. Second International Study of Infarct Survival Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol. 1988,12:(suppl A):3A-13A.
33. The Multicenfer Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med. 1988,319.385-392.
34. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
35. International Study of Infarct Survival Collaborative Group. Results of a large randomized trial of intravenous streptokinase and oral aspirin in acute myocardial infarction. J Am Coll Cardiol. 1988;11.232. Abstract.
36. Moss AJ and the Multicenter Diltiazem Post-infarction Research Group. Long-term effect of diltiazem on mortality and reinfarction after myocardial infarction: the MDPIT Study. J Am Coll Cardiol. 1988;11 27 Abstract.
37. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetylsalicyclic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436-440.
38. The Coronary Drug Project Research Group. Aspirin in coronary heart disease J Chronic Dis. 1976;29:625-642.
39. Elwood PC, Sweetnam PM,. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2:1313-1315.
40. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980;62.449-461.
41. Breddin K, Loew D, Lechner K, Liberia K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetyl-salicylic acid, placebo, and phenprocoumon. Haemostasis. 1980;9:325-344.
42. Elwood PC. British studies of aspirin and myocardial infarction. Am J Med. 1983;7:50-54.
43. International Study of Infarct Survival Pilot Study Investigators. Randomized factorial trial of high dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J. 1987;8:634-642.
44. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction JAMA. 1992;268:1417-1422.
45. Friedman L, Wenger NK, Knatterud GL Impact of the coronary drug project findings on clinical practice. Control Clin Trials. 1983;4:513-522.
46. Becker MH. Factors affecting diffusion of innovations among health professionals. Am J Public Health. 1970;60:294-304.
47. Rogers EM. Diffusion of Innovations. New York, NY: The Free Press; 1983:1-86.
48. Coleman JS, Katz E, Menzel H. Medical Innovation: A Diffusion Study Indianapolis, Ind: Bobbs-Merrill; 1966.
49. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet. 1993,342:891-894.
50. US Congress Office of Technology Assessment. The Impact of Randomized Clinical Trials on Health Policy and Medical Practice Washington, DC: US Government Printing Office: 1983. Office of Technology Assessment publication BP-H-22
51. Bunker JP, Barnes BA, Mosteller F, eds. Progress in surgery and anesthesia, benefits and risks of innovative therapy In Costs, Risks, and Benefits of Surgery New York, NY: Oxford University Press Inc; 1977:124.